MX2022009527A - Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. - Google Patents
Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.Info
- Publication number
- MX2022009527A MX2022009527A MX2022009527A MX2022009527A MX2022009527A MX 2022009527 A MX2022009527 A MX 2022009527A MX 2022009527 A MX2022009527 A MX 2022009527A MX 2022009527 A MX2022009527 A MX 2022009527A MX 2022009527 A MX2022009527 A MX 2022009527A
- Authority
- MX
- Mexico
- Prior art keywords
- psilocin
- derivatives
- treatment
- cns disorders
- serotonergic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969934P | 2020-02-04 | 2020-02-04 | |
| PCT/CA2021/050123 WO2021155468A1 (en) | 2020-02-04 | 2021-02-04 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009527A true MX2022009527A (es) | 2022-11-16 |
Family
ID=77199666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009527A MX2022009527A (es) | 2020-02-04 | 2021-02-04 | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| MX2022009526A MX2022009526A (es) | 2020-02-04 | 2021-02-04 | Derivados de psilocina como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009526A MX2022009526A (es) | 2020-02-04 | 2021-02-04 | Derivados de psilocina como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
Country Status (12)
| Country | Link |
|---|---|
| US (10) | US11427604B2 (enExample) |
| EP (2) | EP4100390A4 (enExample) |
| JP (5) | JP2023513679A (enExample) |
| KR (3) | KR20220137083A (enExample) |
| CN (3) | CN115427395A (enExample) |
| AU (2) | AU2021215811A1 (enExample) |
| BR (2) | BR112022015377A2 (enExample) |
| CA (2) | CA3166933A1 (enExample) |
| IL (3) | IL327334A (enExample) |
| MX (2) | MX2022009527A (enExample) |
| PH (1) | PH12022551981A1 (enExample) |
| WO (2) | WO2021155470A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| DK4172145T3 (da) | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| AU2021328726A1 (en) * | 2020-08-21 | 2023-03-02 | Compass Pathfinder Limited | Novel psilocin derivatives having prodrug properties |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022115944A1 (en) | 2020-12-01 | 2022-06-09 | Magicmed Industries Inc. | Carboxylated psilocybin derivatives and methods of using |
| EP4031529B1 (en) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| WO2022155751A1 (en) | 2021-01-22 | 2022-07-28 | Magicmed Industries Inc. | Prenylated psilocybin derivatives and methods of using |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| MX2023010317A (es) * | 2021-03-02 | 2023-11-09 | Mindset Pharma Inc | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| US20220370413A1 (en) * | 2021-03-06 | 2022-11-24 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| AU2022239825C1 (en) * | 2021-03-18 | 2026-08-13 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| CN117177959A (zh) * | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | 裸头草碱类似物、盐、组合物和使用方法 |
| US20240174607A1 (en) * | 2021-03-18 | 2024-05-30 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| KR20240065084A (ko) * | 2021-08-20 | 2024-05-14 | 테란 바이오사이언시스 인코포레이티드 | 사일로신의 전구약물 및 유도체 및 그의 용도 |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| US11344564B1 (en) | 2021-08-20 | 2022-05-31 | Lennham Pharmaceuticals, Inc. | Method of treatment based on reduced monoamine oxidase a activity |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| WO2023077245A1 (en) * | 2021-11-08 | 2023-05-11 | Nova Mentis Life Science Corp. | Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| AU2022408191B2 (en) * | 2021-12-10 | 2025-05-15 | Caamtech, Inc. | Psilocybin derivatives |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023133873A1 (en) * | 2022-01-17 | 2023-07-20 | Nokia Shanghai Bell Co., Ltd. | Configuration for in-x subnetworks |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| WO2023214404A1 (en) * | 2022-05-01 | 2023-11-09 | Short Wave Pharma Inc. | A mucoadhesive film comprising a pharmaceutically active agent and uses thereof |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CA3267605A1 (en) * | 2022-09-12 | 2024-03-21 | Bionxt Solutions Inc. | PSILOCIN DERIVATIVES BASED ON AMINO ACIDS AND CARBOHYDRATES |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| EP4704833A2 (en) * | 2023-04-27 | 2026-03-11 | ATAI Therapeutics, Inc. | Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| CN121793958A (zh) * | 2023-06-27 | 2026-04-03 | 帕多瓦大学 | 使用二甲-4-羟色胺磷酸的联合疗法 |
| JP2026524104A (ja) | 2023-06-28 | 2026-07-17 | サイロ プロプリエタリー リミテッド | 化合物 |
| EP4735441A1 (en) | 2023-06-28 | 2026-05-06 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| EP4746873A1 (en) * | 2023-07-19 | 2026-05-27 | ATAI Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| TW202519206A (zh) * | 2023-11-06 | 2025-05-16 | 大陸商宜昌人福藥業有限責任公司 | 一種n,n-二甲基色胺衍生物及其藥物組合物、製備方法和用途 |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US12310974B1 (en) | 2023-12-19 | 2025-05-27 | Samuel Aballea | Method of treating post-traumatic stress disorder with carpipramine |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1242318A (en) | 1913-12-20 | 1917-10-09 | Sam Brest | Ash sifter and receptacle. |
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US3078214A (en) * | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| GB933286A (en) | 1961-03-23 | 1963-08-08 | Lodge Cottrell Ltd | Improvements in and relating to electro-precipitation |
| CH414639A (de) * | 1961-10-20 | 1966-06-15 | Sandoz Ag | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |
| US3202675A (en) | 1961-10-26 | 1965-08-24 | Sterling Drug Inc | 1-benzyl-2, 5-bis (chloromethyl) pyrrolidine and acid-addition salts thereof |
| BE615395A (enExample) | 1962-03-21 | |||
| GB990092A (en) | 1962-10-24 | 1965-04-22 | Roche Products Ltd | Novel indole derivatives and a process for the manufacture thereof |
| WO2005062985A2 (en) * | 2003-12-23 | 2005-07-14 | American Bioscience, Inc. | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| US7429575B2 (en) | 2006-01-10 | 2008-09-30 | Yu Ruey J | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| EP2014662A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| RU2016129380A (ru) * | 2013-12-20 | 2018-01-25 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием |
| ES2882588T3 (es) | 2015-03-31 | 2021-12-02 | Turtle Bear Holdings Llc | Actividad antiviral de setas medicinales y sus constituyentes activos |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| CZ307719B6 (cs) | 2015-12-31 | 2019-03-20 | Vysoká škola chemicko-technologická v Praze | Použití derivátu tryptaminu |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3077053A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Methods and compositions for inhibition of stat3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| US20230021957A1 (en) | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| US20210236523A1 (en) | 2020-02-05 | 2021-08-05 | Yale University | Psychedelic treatment for headache disorders |
| KR20230005367A (ko) | 2020-05-04 | 2023-01-09 | 트러스티즈 오브 터프츠 칼리지 | 뇌 전달을 위한 합성 지질-유사 물질 |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20220169606A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Compositions and compounds for bioanalysis |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US20220168274A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Parenteral Formulation |
| DK4172145T3 (da) | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| AU2021328726A1 (en) * | 2020-08-21 | 2023-03-02 | Compass Pathfinder Limited | Novel psilocin derivatives having prodrug properties |
| EP4138818B1 (en) | 2020-08-28 | 2024-08-21 | Cybin UK Ltd | Injectable formulation |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255421A1 (en) | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| CA3201913A1 (en) * | 2020-12-09 | 2022-06-16 | Andrew R. Chadeayne | Dialkyl trytamines and their therapeutic uses |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-02-04 MX MX2022009527A patent/MX2022009527A/es unknown
- 2021-02-04 JP JP2022548056A patent/JP2023513679A/ja active Pending
- 2021-02-04 WO PCT/CA2021/050125 patent/WO2021155470A1/en not_active Ceased
- 2021-02-04 CN CN202180026581.4A patent/CN115427395A/zh active Pending
- 2021-02-04 EP EP21750671.6A patent/EP4100390A4/en active Pending
- 2021-02-04 BR BR112022015377A patent/BR112022015377A2/pt unknown
- 2021-02-04 IL IL327334A patent/IL327334A/en unknown
- 2021-02-04 CA CA3166933A patent/CA3166933A1/en active Pending
- 2021-02-04 EP EP21751268.0A patent/EP4100391A4/en active Pending
- 2021-02-04 PH PH1/2022/551981A patent/PH12022551981A1/en unknown
- 2021-02-04 WO PCT/CA2021/050123 patent/WO2021155468A1/en not_active Ceased
- 2021-02-04 JP JP2022548057A patent/JP2023513680A/ja active Pending
- 2021-02-04 KR KR1020227030616A patent/KR20220137083A/ko not_active Ceased
- 2021-02-04 MX MX2022009526A patent/MX2022009526A/es unknown
- 2021-02-04 KR KR1020247004116A patent/KR20240023678A/ko not_active Ceased
- 2021-02-04 KR KR1020227030603A patent/KR20220137081A/ko not_active Ceased
- 2021-02-04 CN CN202180026575.9A patent/CN115397810A/zh active Pending
- 2021-02-04 AU AU2021215811A patent/AU2021215811A1/en active Pending
- 2021-02-04 AU AU2021217424A patent/AU2021217424A1/en active Pending
- 2021-02-04 CN CN202310101242.9A patent/CN115974757A/zh active Pending
- 2021-02-04 BR BR112022015375A patent/BR112022015375A2/pt unknown
- 2021-02-04 CA CA3166936A patent/CA3166936A1/en active Pending
- 2021-07-28 US US17/387,845 patent/US11427604B2/en active Active
- 2021-07-28 US US17/387,883 patent/US20220024956A1/en active Pending
-
2022
- 2022-05-13 US US17/743,718 patent/US11597738B2/en active Active
- 2022-06-06 US US17/833,341 patent/US11591353B2/en active Active
- 2022-08-04 IL IL295364A patent/IL295364B2/en unknown
- 2022-08-04 IL IL295371A patent/IL295371B2/en unknown
- 2022-12-12 US US18/079,617 patent/US12054505B2/en active Active
-
2023
- 2023-01-27 US US18/102,359 patent/US20230167141A1/en not_active Abandoned
- 2023-02-15 US US18/109,890 patent/US20230203070A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024015076A patent/JP2024054193A/ja active Pending
- 2024-05-30 US US18/678,114 patent/US12378266B2/en active Active
- 2024-12-16 US US18/982,452 patent/US20250388611A1/en active Pending
-
2025
- 2025-06-11 US US19/235,150 patent/US20260116901A1/en active Pending
- 2025-10-10 JP JP2025172009A patent/JP2026010068A/ja active Pending
- 2025-12-09 JP JP2025243928A patent/JP2026053405A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551981A1 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| MX2023006652A (es) | Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. | |
| MX2023010316A (es) | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. | |
| MX2025001439A (es) | Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos | |
| MX2021010674A (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos. | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| MX2023013245A (es) | Rescorcinoles, metodos para su fabricacion, y usos de los mismos. | |
| MX2024012865A (es) | Derivados de indolina como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| ZA202400595B (en) | Spirocyclic compounds | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| MX2009005252A (es) | Aminopirrolidinas como antagonistas del receptor de quimiocina. | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| ATE549311T1 (de) | Amino-propanolderivative als modulatoren des sphingosin-1-phosphat-rezeptors | |
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| PH12022500015A1 (en) | Ccr6 receptor modulators | |
| NO20092149L (no) | Spiro-piperidinderivater | |
| MX2024014435A (es) | Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington | |
| MX2024010344A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2025001465A (es) | Dimeros de 3-pirrolidina-indol como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos |